You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 12, 2025

Claims for Patent: 11,813,275

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,813,275

Title:	Pharmaceutical composition, methods for treating and uses thereof
Abstract:	The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
Inventor(s):	Uli Christian BROEDL, Odd-Erik JOHANSEN, Gabriel Woojai KIM, Eric Williams Mayoux, Afshin SALSALI, Nima Soleymanlou, Maximilian von EYNATTEN, Hans-Juergen Woerle, David Z.I. CHERNEY, Bruce A. PERKINS, Andreas DAIBER, Thomas MUENZEL
Assignee:	Boehringer Ingelheim International GmbH
Application Number:	US17/381,498
Patent Claims:	1. A method for reducing the risk of cardiovascular death and/or hospitalization for heart failure in a patient with heart failure, said method comprising administering a therapeutically effective amount of empagliflozin to the patient. 2. The method according to claim 1, wherein empagliflozin is administered orally in a total daily amount of 10 mg or 25 mg. 3. The method according to claim 1, wherein the patient is diagnosed with type 2 diabetes mellitus. 4. The method according to claim 1, wherein the method reduces the risk of cardiovascular death. 5. The method according to claim 1, wherein the method reduces the risk of hospitalization for heart failure. 6. The method according to claim 1, wherein empagliflozin is administered orally in a total daily amount of 10 mg. 7. The method according to claim 1, wherein the patient is an adult patient.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.